Skip to main content
Premium Trial:

Request an Annual Quote

Dicerna Pharmaceuticals Raises Additional $4M in Series B, Bringing Total to $29M

Premium

Dicerna Pharmaceuticals said this week that it has raised an additional $4 million in a second closing of Series B equity financing, bringing the total raised in this round to $29 million.

The company raised $25 million in the Series B in August (GSN 8/12/2010).

SR One, the venture capital arm of GlaxoSmithKline, participated in the financing as a new investor, joining existing investors Oxford Bioscience Partners, Skyline Ventures, Abingworth, and Domain Associates.

In conjunction with the investment, Brian Gallagher, a partner at SR One, will become an observer on Dicerna's board of directors.

Doug Fambrough, CEO of Dicerna, said in a statement that the company re-opened the Series B round "due to significant additional interest from the investment community in our unique Dicer Substrate Technology platform and next generation approach to developing RNAi therapeutics."

Dicerna said it plans to use the proceeds from the financing to further develop its lead in-house program in oncology and to improve its delivery technologies.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.